Literature DB >> 11250530

Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study.

R Channick1, D B. Badesch, V F. Tapson, G Simonneau, I Robbins, A Frost, S Roux, M Rainisio, F Bodin, L J. Rubin.   

Abstract

Entities:  

Year:  2001        PMID： 11250530     DOI： 10.1016/s1053-2498(00)00606-9

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN： 1053-2498            Impact factor:   10.247


× No keyword cloud information.
  19 in total

Review 1.  Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.

Authors:  Ezequiel Balmori Melian; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  [Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis].

Authors:  G Riemekasten; H Schulze-Koops
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

3.  Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis.

Authors:  Edward A Pankey; Matthew Epps; Bobby D Nossaman; Albert L Hyman; Philip J Kadowitz
Journal:  J Clin Rheumatol Musculoskelet Med       Date:  2010-12-01

Review 4.  Endothelin receptor antagonists and cardiovascular diseases of aging.

Authors:  M P Love; J J McMurray
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

5.  Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension.

Authors:  Meghan M Cirulis; John J Ryan
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

6.  Pediatric Primary Pulmonary Hypertension.

Authors:  Andrew J. Maxwell; Nancy D. Bridges
Journal:  Curr Treat Options Cardiovasc Med       Date:  2001-10

7.  [Therapy of pulmonary arterial hypertension].

Authors:  H Olschewski; A Ghofrani; B Enke; F Reichenberger; R Voswinckel; A Kreckel; S Ghofrani; R Wiedemann; R Schulz; F Grimminger; W Seeger
Journal:  Internist (Berl)       Date:  2005-03       Impact factor: 0.743

Review 8.  The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.

Authors:  Jeremy A Falk; Kiran J Philip; Ernst R Schwarz
Journal:  Vasc Health Risk Manag       Date:  2010-05-06

9.  Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening.

Authors:  Luise Holzhauser; Ronald Zolty
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

10.  Bosentan, a mixed endothelin receptor antagonist, inhibits superoxide anion-induced pain and inflammation in mice.

Authors:  Karla G G Serafim; Suelen A Navarro; Ana C Zarpelon; Felipe A Pinho-Ribeiro; Victor Fattori; Thiago M Cunha; Jose C Alves-Filho; Fernando Q Cunha; Rubia Casagrande; Waldiceu A Verri
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-08-06       Impact factor: 3.000
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.